Novavax, Inc.
Novavax, Inc. (NVAX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nvax · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Novavax, Inc. (NVAX) measures how much investors pay for each dollar of the company's trailing earnings. NVAX's current PE ratio of N/A is calculated by dividing its stock price of $8.81 by its TTM earnings per share of -$0.54.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Novavax, Inc.You NVAX | $1.4B | N/A | — | -$0.54 |
 CureVac N.V. CVAC | $1.0B | 4.56x | — | $0.72 |
 Nektar Therapeutics NKTR | $1.1B | N/A | — | -$9.73 |
 Intellia Therapeutics, Inc. NTLA | $1.5B | N/A | — | -$3.81 |
 ORIC Pharmaceuticals, Inc. ORIC | $774M | N/A | — | -$1.47 |
 Precigen, Inc. PGEN | $1.1B | N/A | — | -$0.82 |
 Terns Pharmaceuticals, Inc. TERN | $4.8B | N/A | — | -$1.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 2.47x | $2.72 | — | |
2024-12-31 FY2024 | — | $-1.23 | — | |
2023-12-31 FY2023 | — | $-5.41 | — | |
2022-12-31 FY2022 | — | $-8.42 | — | |
2021-12-31 FY2021 | — | $-23.44 | — | |
2020-12-31 FY2020 | — | $-7.27 | — | |
2019-12-31 FY2019 | — | $-5.40 | — | |
2018-12-31 FY2018 | — | $-9.99 | — | |
2017-12-31 FY2017 | — | $-12.56 | — | |
2016-12-31 FY2016 | — | $-20.68 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Novavax, Inc. (NVAX) measures how much investors pay for each dollar of the company's trailing earnings. NVAX's current PE ratio of N/A is calculated by dividing its stock price of $8.81 by its TTM earnings per share of -$0.54.
Frequently asked questions
NVAX pe ratio · 6 questionsNVAX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $8.81 and TTM EPS of -$0.54. Data sourced from Financial Modeling Prep via NVAX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Novavax, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08